Clinical Trial Update: Extended Dosing With Eltrombopag for Severe Aplastic Anemia [Phase 2]

View source ↗

Summary

Phase 2 trial update on extended dosing of eltrombopag for severe aplastic anemia completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Severe Aplastic Anemia (SAA) | Phase 2 | Status: COMPLETED | Results posted: 2018-12-04